‼️Their fringe views are inhumane, unethical junk science that promotes harm
‼️They complain that they've been marginalized but this is simply untrue
‼️I am sick of people telling me we have to "listen to both sides." There aren't 2 sides here 2/n
If this is true raises the question of why certain (fringe & unethical) views got access to No.10 while others were ignored... https://t.co/A75HrSEqo4
— Prof. Devi Sridhar (@devisridhar) December 13, 2020
Focused Protection: The Middle Ground between Lockdowns and "Let-it-rip". An essay by Jay Bhattacharya (@Stanford), @SunetraGupta (@UniofOxford) and @MartinKulldorff (@Harvard). https://t.co/T8uLxSFwgh
— Martin Kulldorff (@MartinKulldorff) December 11, 2020
While looking at speculative pharmaceutical stocks I am reminded of why I am averse to these risky picks.#DDDD was compelling enough, though, to break this rule. The 10+ treatments under trial, industry-leading IP portfolio, and comparable undervaluation are inescapable.
— Shrey Srivastava (@BlogShrey) December 16, 2020